LEGENDS
FIGURE 1 Effect of daratumumab on the patient’s total white
cell count (x 109/L) and absolute (peripheral) blast
count (x 109/L) over time in days: 2 doses of
daratumumab administered on day 1 and day 8, with an initial reduction
in WCC and ABC between day 3 and day 10. WCC and ABC rose from day 11
until FLA-Ida commenced at day 14. See Supplemental table 1 for further
laboratory values. WCC, white cell count; ABC, absolute blast count;
Dara, daratumumab; FLA-Ida, fludarabine, high-dose cytarabine,
idarubicin